Good morning :)
Place Order
Add to Watchlist

Kilitch Drugs (India) Ltd

KILITCH Share Price

454.500.01% (-0.05)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹729 cr, stock is ranked 1,620

Stock is 3.20x as volatile as Nifty

KILITCH Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹729 cr, stock is ranked 1,620

Stock is 3.20x as volatile as Nifty

KILITCH Performance & Key Metrics

KILITCH Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.734.16
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.216.660.83%

KILITCH Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

KILITCH Company Profile

Kilitch Drugs (India) Limited is engaged in the development and operations of pharmaceutical business. The Company's services range from manufacturing to marketing a host of formulations in solid, liquid and parenteral forms.

KILITCH Similar Stocks (Peers)

Compare with peers Compare with peers 

KILITCH Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
87.88
87.88
PE Ratio
23.03
23.03
1Y Return
2.38%
2.38%
Buy Reco %
74.19
74.19
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
56.67
56.67
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
72.00
72.00
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
81.25
81.25
Compare with Peers

KILITCH Sentiment Analysis

KILITCH Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

KILITCH Stock Summary · June 2024

Kilitch Drugs India Limited is strategically positioned for growth, particularly in the Ethiopian market, where it holds a unique competitive advantage as the sole supplier of Cephalosporin. Despite facing challenges with declining standalone revenue in Q4 FY24, the company anticipates a robust year-on-year growth of 25%-30% for FY25, bolstered by significant government contracts and an expanding product portfolio. Operational enhancements, including a new manufacturing facility in Khopoli and increased capacity at the Mumbai plant, are expected to drive efficiency and revenue. The proactive approach to working capital management, coupled with a focus on regulatory compliance, underscores the company's commitment to sustaining stakeholder confidence and optimizing financial performance. Overall, the sentiment remains optimistic, reflecting confidence in future revenue generation and market expansion.

KILITCH Stock Growth Drivers
KILITCH Stock Growth Drivers
7
  • Expansion of Manufacturing Capabilities

    Kilitch Drugs India Limited has successfully expanded its manufacturing capabilities, including the establishment of a

  • Successful International Business Growth

    The company has achieved significant growth in its international business, securing new product approvals and

KILITCH Stock Challenges
KILITCH Stock Challenges
3
  • Decline in Q4 Financial Performance

    In Q4 FY 2023-24, the company reported a decline in standalone total operating revenue, which

  • Mixed Annual Financial Results

    For the full financial year 2023-24, while the company saw an increase in total operating

KILITCH Forecast

KILITCH Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

KILITCH

KILITCH

Income

Balance Sheet

Cash Flow

KILITCH Income Statement

KILITCH Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.93%, vs industry avg of 9.02%

Constant Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.04%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 30.75%, vs industry avg of 15.29%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue29.7953.8986.4957.4571.19117.14142.52158.85209.48209.48
Raw Materialssubtract10.5026.4448.3529.8236.2265.4874.5379.08166.85167.23
Power & Fuel Costsubtract1.061.111.421.621.571.922.152.43
Employee Costsubtract3.384.305.285.695.246.1811.7310.01
Selling & Administrative Expensessubtract6.988.1912.5611.5011.1715.3423.5328.24
Operating & Other expensessubtract7.275.287.604.289.0114.819.9310.35
Depreciation/Amortizationsubtract9.762.042.052.001.992.473.553.353.113.12
Interest & Other Itemssubtract0.160.420.650.940.881.335.086.045.045.04
Taxes & Other Itemssubtract-0.430.964.760.771.462.251.564.757.777.77
EPS-6.723.822.630.542.364.746.719.2216.6016.37
DPS0.000.500.500.000.000.000.000.000.000.00
Payout ratio0.000.130.190.000.000.000.000.000.000.00

KILITCH Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
 

KILITCH Stock Peers

KILITCH Past Performance & Peer Comparison

KILITCH Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Kilitch Drugs (India) Ltd27.334.16
Sun Pharmaceutical Industries Ltd37.006.030.95%
Cipla Ltd23.034.531.06%
Dr Reddy's Laboratories Ltd20.024.010.59%

KILITCH Stock Price Comparison

Compare KILITCH with any stock or ETF
Compare KILITCH with any stock or ETF
KILITCH
Loading...

KILITCH Holdings

KILITCH Shareholdings

KILITCH Promoter Holdings Trend

KILITCH Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

KILITCH Institutional Holdings Trend

KILITCH Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

KILITCH Shareholding Pattern

KILITCH Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding69.23%0.00%0.00%0.00%30.77%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

KILITCH Shareholding History

KILITCH Shareholding History

Dec '23MarJunSepDec '24Mar0.00%0.00%0.00%0.00%0.00%0.00%

KILITCH Insider Trades & Bulk Stock Deals

KILITCH Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing KILITCH stock

smallcases containing KILITCH stock

Looks like this stock is not in any smallcase yet.

KILITCH Events

KILITCH Events

KILITCH Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

KILITCH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

KILITCH Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

KILITCH has not given any dividends in last 5 years

KILITCH Upcoming Dividends

KILITCH Upcoming Dividends

No upcoming dividends are available

KILITCH Past Dividends

KILITCH Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 20, 2019

Cash Dividend

Ex DateEx DateSep 18, 2018

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 18, 2018

Cash Dividend

Ex DateEx DateSep 24, 2012

Special
Special | Div/Share: ₹30.00

Dividend/Share

30.00

Ex DateEx Date

Sep 24, 2012

Cash Dividend

Ex DateEx DateAug 18, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Aug 18, 2011

Cash Dividend

Ex DateEx DateOct 14, 2010

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Oct 14, 2010

KILITCH Stock News & Opinions

KILITCH Stock News & Opinions

Earnings
Kilitch Drugs (India) consolidated net profit rises 189.69% in the March 2025 quarter

Net profit of Kilitch Drugs (India) rose 189.69% to Rs 10.40 crore in the quarter ended March 2025 as against Rs 3.59 crore during the previous quarter ended March 2024. Sales rose 36.61% to Rs 61.23 crore in the quarter ended March 2025 as against Rs 44.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 82.88% to Rs 26.70 crore in the year ended March 2025 as against Rs 14.60 crore during the previous year ended March 2024. Sales rose 28.47% to Rs 198.32 crore in the year ended March 2025 as against Rs 154.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales61.2344.82 37 198.32154.37 28 OPM %23.8315.80 -15.8715.64 - PBDT14.696.23 136 37.5822.70 66 PBT13.845.30 161 34.4719.35 78 NP10.403.59 190 26.7014.60 83 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit rises 104.81% in the December 2024 quarter

Net profit of Kilitch Drugs (India) rose 104.81% to Rs 5.96 crore in the quarter ended December 2024 as against Rs 2.91 crore during the previous quarter ended December 2023. Sales rose 76.69% to Rs 56.17 crore in the quarter ended December 2024 as against Rs 31.79 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales56.1731.79 77 OPM %15.547.17 - PBDT9.063.64 149 PBT8.252.82 193 NP5.962.91 105 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit rises 81.86% in the September 2024 quarter

Net profit of Kilitch Drugs (India) rose 81.86% to Rs 8.62 crore in the quarter ended September 2024 as against Rs 4.74 crore during the previous quarter ended September 2023. Sales rose 15.22% to Rs 47.47 crore in the quarter ended September 2024 as against Rs 41.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales47.4741.20 15 OPM %12.8520.92 - PBDT10.957.60 44 PBT10.356.78 53 NP8.624.74 82 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) announces board meeting date

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene AGM

Kilitch Drugs (India) announced that the 32th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

9 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit declines 60.12% in the June 2024 quarter

Net profit of Kilitch Drugs (India) declined 60.12% to Rs 1.34 crore in the quarter ended June 2024 as against Rs 3.36 crore during the previous quarter ended June 2023. Sales declined 8.51% to Rs 33.45 crore in the quarter ended June 2024 as against Rs 36.56 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.4536.56 -9 OPM %4.9616.90 - PBDT2.505.24 -52 PBT1.654.53 -64 NP1.343.36 -60 Powered by Capital Market - Live

10 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to conduct board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live

10 months agoCapital Market - Live

Krebs Biochemicals & Industries Ltd leads gainers in ‘B’ group

10 months agoBusiness Standard

Frequently asked questions

Frequently asked questions

  1. What is the share price of Kilitch Drugs (India) Ltd (KILITCH) today?

    The share price of KILITCH as on 13th June 2025 is ₹454.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Kilitch Drugs (India) Ltd (KILITCH) share?

    The past returns of Kilitch Drugs (India) Ltd (KILITCH) share are
    • Past 1 week: 2.58%
    • Past 1 month: 8.34%
    • Past 3 months: 44.47%
    • Past 6 months: 40.04%
    • Past 1 year: 36.00%
    • Past 3 years: 184.06%
    • Past 5 years: 293.51%

  3. What are the peers or stocks similar to Kilitch Drugs (India) Ltd (KILITCH)?
  4. What is the market cap of Kilitch Drugs (India) Ltd (KILITCH) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kilitch Drugs (India) Ltd (KILITCH) is ₹729.98 Cr as of 13th June 2025.

  5. What is the 52 week high and low of Kilitch Drugs (India) Ltd (KILITCH) share?

    The 52-week high of Kilitch Drugs (India) Ltd (KILITCH) is ₹499 and the 52-week low is ₹299.95.

  6. What is the PE and PB ratio of Kilitch Drugs (India) Ltd (KILITCH) stock?

    The P/E (price-to-earnings) ratio of Kilitch Drugs (India) Ltd (KILITCH) is 27.33. The P/B (price-to-book) ratio is 4.16.

  7. Which sector does Kilitch Drugs (India) Ltd (KILITCH) belong to?

    Kilitch Drugs (India) Ltd (KILITCH) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Kilitch Drugs (India) Ltd (KILITCH) shares?

    You can directly buy Kilitch Drugs (India) Ltd (KILITCH) shares on Tickertape. Simply sign up, connect your demat account and place your order.